Payment overview · 2025
General Payments
$3,103.67
180 reported records · 34 companies
Healthcare provider profile · identity verified
Max E. Mercado, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PHILADELPHIA, PA · NPI 1336151182
Verified facts
What the public records show
CMS Open Payments records show Max E. Mercado, M.D. received $3,103.67 in general payments during 2025 across 180 reported records.
ABBVIE INC. accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 51 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Prolia, Qulipta, Rexulti, Rybelsus, Trelegy Ellipta, Ubrelvy, Verquvo, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 313 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 538 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 313 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $496.81 | 16.0% | 31 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $326.04 | 10.5% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $231.38 | 7.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $203.03 | 6.5% | 20 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $199.11 | 6.4% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $189.50 | 6.1% | 8 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $169.11 | 5.5% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $157.70 | 5.1% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $101.96 | 3.3% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $92.58 | 3.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $81.30 | 2.6% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $80.28 | 2.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $79.04 | 2.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $68.00 | 2.2% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $62.18 | 2.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $56.43 | 1.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.22 | 1.7% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $49.42 | 1.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.03 | 1.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $44.12 | 1.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.54 | 1.1% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $32.87 | 1.1% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.48 | 1.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $28.41 | 0.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $27.79 | 0.9% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.08 | 0.7% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $19.53 | 0.6% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.32 | 0.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.83 | 0.6% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.50 | 0.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.24 | 0.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.08 | 0.5% | 1 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $13.98 | 0.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.78 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,019.59 | 178 |
| Travel and Lodging | $84.08 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $262.56 | 14 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $199.11 | 15 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $199.11 | 15 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $199.11 | 15 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $187.58 | 12 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $169.11 | 16 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $166.77 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $166.77 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $157.70 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $157.07 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $157.07 | 10 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $152.16 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $137.73 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.31 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $103.87 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $103.87 | 14 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $102.31 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $101.96 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $99.16 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $92.58 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $80.28 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $79.04 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $75.13 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $68.18 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $68.00 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $63.48 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $62.18 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $49.42 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $48.03 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $44.12 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $32.48 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $28.41 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $13.98 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 313 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 181 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 167 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 261 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 191 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 538 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 29 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 111 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 202 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
261 | 63 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
29 | 23 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
181 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 32 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
313 | 60 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
202 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
191 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
203 | 29 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
538 | 74 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
111 | 19 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
313 | 60 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1386 | 302 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 886 | 148 |
| Omeprazole | Omeprazole | 811 | 154 |
| Fluticasone Propionate | Fluticasone Propionate | 776 | 242 |
| Atorvastatin Calcium | Atorvastatin Calcium | 747 | 174 |
| Montelukast Sodium | Montelukast Sodium | 594 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 578 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 561 | 144 |
| Gabapentin | Gabapentin | 560 | 116 |
| Ozempic | Semaglutide | 538 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 522 | 100 |
| Trazodone Hcl | Trazodone Hcl | 480 | 92 |
| Alprazolam | Alprazolam | 451 | 57 |
| Zolpidem Tartrate | Zolpidem Tartrate | 450 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 426 | 96 |
| Lisinopril | Lisinopril | 423 | 93 |
| Endocet | Oxycodone Hcl/Acetaminophen | 413 | 54 |
| Pregabalin | Pregabalin | 381 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 330 | 64 |
| Eliquis | Apixaban | 313 | 60 |
| Losartan Potassium | Losartan Potassium | 313 | 75 |
| Metformin Hcl | Metformin Hcl | 268 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 268 | 55 |
| Azithromycin | Azithromycin | 264 | 209 |
| Linzess | Linaclotide | 261 | 63 |
| Meloxicam | Meloxicam | 259 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 253 | 54 |
| Azelastine Hcl | Azelastine Hcl | 242 | 71 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 235 | 44 |
| Tramadol Hcl | Tramadol Hcl | 234 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 231 | 61 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 229 | 35 |
| Furosemide | Furosemide | 225 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 224 | 46 |
| Famotidine | Famotidine | 219 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 209 | 59 |
| Trulicity | Dulaglutide | 203 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 202 | 44 |
| Mounjaro | Tirzepatide | 191 | 38 |
| Nebivolol Hcl | Nebivolol Hcl | 184 | 33 |
| Farxiga | Dapagliflozin Propanediol | 181 | 38 |
| Meclizine Hcl | Meclizine Hcl | 180 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 180 | 45 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 179 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 173 | 47 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 170 | 59 |
| Carvedilol | Carvedilol | 168 | 37 |
| Jardiance | Empagliflozin | 167 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 166 | 40 |
| Sertraline Hcl | Sertraline Hcl | 162 | 37 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 158 | 37 |
| Donepezil Hcl | Donepezil Hcl | 158 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 45 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 156 | 29 |
| Clonazepam | Clonazepam | 150 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 30 |
| Tresiba Flextouch U-200 | Insulin Degludec | 149 | 22 |
| Ezetimibe | Ezetimibe | 138 | 30 |
| Icosapent Ethyl | Icosapent Ethyl | 137 | 29 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 132 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 132 | 43 |
| Valsartan | Valsartan | 129 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 126 | 14 |
| Edarbi | Azilsartan Medoxomil | 125 | 24 |
| Januvia | Sitagliptin Phosphate | 124 | 27 |
| Risedronate Sodium | Risedronate Sodium | 122 | 23 |
| Ibuprofen | Ibuprofen | 121 | 29 |
| Metformin Hcl Er | Metformin Hcl | 119 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 117 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 117 | 29 |
| Sucralfate | Sucralfate | 117 | 26 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 116 | 24 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 112 | 27 |
| Rybelsus | Semaglutide | 111 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 109 | 21 |
| Clobetasol Propionate | Clobetasol Propionate | 106 | 23 |
| Lorazepam | Lorazepam | 106 | 21 |
| Buspirone Hcl | Buspirone Hcl | 105 | 30 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 104 | 18 |
| Mirtazapine | Mirtazapine | 99 | 26 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 97 | 28 |
| Simvastatin | Simvastatin | 95 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 93 | 70 |
| Methylprednisolone | Methylprednisolone | 93 | 76 |
| Entresto | Sacubitril/Valsartan | 92 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 90 | 17 |
| Candesartan Cilexetil | Candesartan Cilexetil | 87 | 22 |
| Nifedipine Er | Nifedipine | 87 | 19 |
| Topiramate | Topiramate | 87 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 26 |
| Ofloxacin | Ofloxacin | 80 | 59 |
| Prednisone | Prednisone | 79 | 23 |
| Amoxicillin | Amoxicillin | 74 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 13 |
| Finasteride | Finasteride | 73 | 15 |
| Bumetanide | Bumetanide | 72 | 12 |
| Spironolactone | Spironolactone | 71 | 14 |
| Celecoxib | Celecoxib | 67 | 12 |
| Alcohol Pads | Alcohol Antiseptic Pads | 66 | 11 |
| Vraylar | Cariprazine Hcl | 65 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | suppressed |
| Xarelto | Rivaroxaban | 64 | 15 |
| Trulance | Plecanatide | 61 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 60 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 56 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 56 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 55 | suppressed |
| Latanoprost | Latanoprost | 55 | suppressed |
| Mupirocin | Mupirocin Calcium | 55 | 28 |
| Alendronate Sodium | Alendronate Sodium | 54 | 13 |
| Naproxen | Naproxen | 54 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 50 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 49 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 11 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 46 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | 13 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 44 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 44 | suppressed |
| Allopurinol | Allopurinol | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Nitroglycerin | Nitroglycerin | 42 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 39 | 20 |
| Baclofen | Baclofen | 39 | 11 |
| Methotrexate | Methotrexate Sodium | 39 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Fluconazole | Fluconazole | 37 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 37 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 13 |
| Carvedilol Er | Carvedilol Phosphate | 36 | suppressed |
| Lidocaine | Lidocaine | 36 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 36 | 13 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | 15 |
| Nystatin | Nystatin | 33 | 14 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 24 |
| Glimepiride | Glimepiride | 31 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Dutasteride | Dutasteride | 30 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 20 |
| Terbinafine Hcl | Terbinafine Hcl | 30 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Prolia | Denosumab | 29 | 23 |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Repatha Pushtronex | Evolocumab | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 25 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 20 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 18 |
| Dapagliflozin-Metformin Er | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 19 | suppressed |
| Erythromycin | Erythromycin Base | 19 | 17 |
| Telmisartan | Telmisartan | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Cyclosporine | Cyclosporine | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | 11 |
| Dexilant | Dexlansoprazole | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Entecavir | Entecavir | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Topiramate Er | Topiramate | 16 | suppressed |
| Verquvo | Vericiguat | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Bystolic | Nebivolol Hcl | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | 11 |
| Olanzapine | Olanzapine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Valtrex | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,103.67 · 180 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AUSTEDO XR, Auvelity, CAMZYOS, CAPLYTA, COMIRNATY, CREON, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GLYCATE, IBSRELA, INSPIRE, JARDIANCE, KISUNLA, Kerendia, Korlym, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Omnipod, Ozempic, PREVNAR 20, PROLIA, QULIPTA, RAYALDEE, RECORLEV, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Rybelsus, TERIPARATIDE, TRELEGY ELLIPTA, TRINTELLIX, Tymlos, UBRELVY, VERQUVO, VIBERZI, VRAYLAR, Veozah, ZAVZPRET, ZENPEP, ZORYVE | 25 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error